Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years (Q35870814)

10 August 2017

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years (English)

1 reference

10 August 2017

0 references

anti-retroviral agent

0 references

9

Amanda Mocroft

1 reference

10 August 2017

Alessandro Cozzi-Lepri

11

Alessandro Cozzi-Lepri

0 references

Daniel Podzamczer

10

Daniel Podzamczer

1 reference

10 August 2017

31

Ard van Sighem

1 reference

10 August 2017

16

Stephane De Wit

1 reference

10 August 2017

Dominique Costagliola

3

Dominique Costagliola

1 reference

10 August 2017

14

Schlomo Staszewski

1 reference

10 August 2017

Rebecca Lodwick

2

0 references

Maria Dorrucci

Maria Dorrucci

7

0 references

Ali Judd

Ali Judd

19

0 references

Dimitrios Paraskevis

Dimitrios Paraskevis

36

0 references

Claire Thorne

Claire Thorne

27

0 references

Santiago Pérez-Hoyos

Santiago Pérez-Hoyos

29

0 references

Antonella Castagna

Antonella Castagna

17

0 references

Jens Lundgren

Jens D Lundgren

40

0 references

Andrea De Luca

Andrea De Luca

35

0 references

Andrea Antinori

18

Andrea Antinori

1 reference

10 August 2017

12

Niels Obel

1 reference

10 August 2017

30

Deenan Pillay

1 reference

10 August 2017

33

Huldrych Günthard

1 reference

10 August 2017

8

Bruno Ledergerber

1 reference

10 August 2017

41

Andrew N Phillips

1 reference

10 August 2017

22

Cristina Mussini

1 reference

10 August 2017

38

Jesper Kjaer

1 reference

10 August 2017

13

Bernard Masquelier

1 reference

10 August 2017

34

Roger Paredes

1 reference

10 August 2017

6

Ramón Teira

1 reference

10 August 2017

20

Jade Ghosn

1 reference

10 August 2017

39

Genèvieve Chêne

1 reference

10 August 2017

4

Peter Reiss

1 reference

10 August 2017

21

Giota Touloumi

1 reference

10 August 2017

25

Laurence Meyer

1 reference

10 August 2017

37

Céline Fabre-Colin

1 reference

10 August 2017

5

Carlo Torti

1 reference

10 August 2017

Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

1

1 reference

10 August 2017

Federico García

15

1 reference

10 August 2017

Xavier Duval

23

1 reference

10 August 2017

José Ramos

24

1 reference

10 August 2017

Josiane Warsawski

26

1 reference

10 August 2017

Joan Masip

28

1 reference

10 August 2017

Sergio Lo Caputo

32

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

10 August 2017

JAMA Internal Medicine

1 reference

10 August 2017

170

1 reference

10 August 2017

5

1 reference

10 August 2017

410-419

1 reference

Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Maraviroc for previously treated patients with R5 HIV-1 infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Raltegravir with optimized background therapy for resistant HIV-1 infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Class-sparing regimens for initial treatment of HIV-1 infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

HIV cohort collaborations: proposal for harmonization of data exchange

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Response to combination antiretroviral therapy: variation by age.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

22 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study

6 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

6 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures

6 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319528

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients

6 December 2018

1 reference

12 December 2020

HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population

1 reference

12 December 2020

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

1 reference

12 December 2020

The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy

1 reference

12 December 2020

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

12 December 2020

10.1001/ARCHINTERNMED.2009.472

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

20212176

1 reference